The purpose of the study is to evaluate the oncological efficacy of pancreatic radiofrequency by the objective response rate (complete and partial responses according to RECIST 1.1.), 5 years after the end of treatment.
Age ≥ 18 years old;
Patient to be treated for a pancreatic tumor by ultrasound-guided RF with a fine needle;
Indication of pancreatic radiofrequency validated in a Multidisciplinary Consultation Meeting;
Patient able to understand the information related to the study;
Patient with a contraindication to radiofrequency treatment;
Pregnant or breastfeeding women
GCS Ramsay Santé pour l'Enseignement et la Recherche
Lead sponsor
Euraxi Pharma
Collaborator